Edgewise Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Fox Jonathan C, was filed 13 Nov 2025.
Who traded when
BuySale+4 other insiders
Since the insiders bought
- +76.8%Entry US$22.75 · Close 21 Oct 2026 US$40.23
- +177.5%Entry US$11.83 · Close at T+365 US$32.83
- -29.0%Entry US$8.92 · Close at T+365 US$6.33
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Edgewise Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$52.62.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 308 shares0Common StockSEC:0001655016-26-000006:0
- 5,781 shares0Common StockSEC:0001853109-26-000001:0
- 7,500 shares0Common StockSEC:0001853109-26-000001:1
- 5,781 shares0Common StockSEC:0001644087-26-000005:0
- 17,969 shares0Common StockSEC:0001185829-26-000001:0
- 5,781 shares0Common StockSEC:0001191702-26-000001:0
- 5,781 shares0Common StockSEC:0001853529-26-000002:0
- 7,031 shares0Common StockSEC:0001644087-26-000005:1
- 21,875 shares0Common StockSEC:0001185829-26-000001:1
- 6,718 shares0Common StockSEC:0001191702-26-000001:1
- 7,031 shares0Common StockSEC:0001853529-26-000002:1
- 2,171 shares@ US$43.79340.0021% mcap28.8% of flowCommon StockSEC:0001853109-26-000001:2
- 304 shares@ US$44.50180.0003% mcap4.1% of flowCommon StockSEC:0001853109-26-000001:3
- 150 shares@ US$44.44330.0001% mcap2.0% of flowCommon StockSEC:0001853109-26-000001:4
- 2,475 shares@ US$43.69840.0024% mcap32.8% of flowCommon StockSEC:0001853109-26-000001:5
- 2,779 shares@ US$43.70730.0027% mcap4.0% of flowCommon StockSEC:0001644087-26-000005:3
- 104 shares@ US$44.42530.0001% mcap0.2% of flowCommon StockSEC:0001644087-26-000005:4
- 800 shares@ US$44.51750.0008% mcap1.2% of flowCommon StockSEC:0001644087-26-000005:5
- 2,919 shares@ US$43.40650.0028% mcap4.1% of flowCommon StockSEC:0001644087-26-000005:6
- 59 shares@ US$44.41420.0001% mcap0.4% of flowCommon StockSEC:0001191702-26-000001:3
- 99 shares@ US$44.50190.0001% mcap0.7% of flowCommon StockSEC:0001191702-26-000001:4
- 2,419 shares@ US$43.79850.0023% mcap17.7% of flowCommon StockSEC:0001191702-26-000001:5
- 2,273 shares@ US$43.67590.0022% mcap3.0% of flowCommon StockSEC:0001853529-26-000002:3
- 2,839 shares@ US$43.7840.0027% mcap4.0% of flowCommon StockSEC:0001644087-26-000005:2
- 8,782 shares@ US$43.64080.0085% mcap48.7% of flowCommon StockSEC:0001185829-26-000001:2
25 of 274 declarations
About Edgewise Therapeutics, Inc.
On March 30, 2021, 5 Edgewise Therapeutics, Inc. filers bought for EUR 27,082,115, including Novo Holdings A/S and James E. Flynn (10% Owner), for EUR 8,529,800 each. The record's 16 purchases total EUR 54,224,302, with a median of EUR 3,264,315; the third largest, EUR 6,791,171 on April 3, 2025, is Orbimed Advisors LLC's (Director). Against them, 141 sales weigh EUR 32,613,333, with a median of EUR 82,373, which puts purchases at 10% of open-market trades.
The three largest sales are all Alan J. Russell's (Chief Scientific Officer): EUR 2,624,768 on December 30, 2024, EUR 1,877,854 on September 20, 2024 and EUR 1,823,044 on November 12, 2025. Russell files 66, of which 52 sales, behind John R. Moore (General Counsel, 70, of which 35 sales).
Read moreShow less
The 270 filings from 17 insiders were published from March 30, 2021 to October 2, 2026, with 94 option exercises. Volume is steady from 2024 to 2026 (49 to 51 a year), against 16 in 2023. Over the last twelve months: 53 filings, 1 purchase, 29 sales. The median delay is 2 days.
For 16 purchases with a stored 90-day result, the median is -11% and 38% are positive: stored past results, not a forecast. This US healthcare and pharma company is worth USD 4.1 billion; insiders hold 0.5% of the capital.
